| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
|
|
|
|
|||||||||||||
|
|
|||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
PAPER |
1 Department of Neurology, Royal Group of Hospitals, Grosvenor Road, Belfast, UK
2 Department of Clinical Neurophysiology, Southern General Hospital, Glasgow, UK
3 General Practitioner, Dumbarton Road, Glasgow
4 Department of Neurology, St Albans City Hospital, Waverley Road, St Albans, Herts, UK
5 Sharoe Green Unit, Lancashire Teaching Hospitals NHS Trust, Preston, Lancashire, UK
6 Royal Group of Hospitals, Grosvenor Road, Belfast
7 Northern Ireland Regional Medical Physics Agency, Royal Group of Hospitals, Grosvenor Road, Belfast
8 Department of Medical Genetics, Belfast City Hospital Trust, Belfast & School of Biological Sciences, University of Ulster, Coleraine, UK
9 Department of Neurology, Royal Group of Hospitals, Grosvenor Road, Belfast
Correspondence to:
Correspondence to:
Dr James I Morrow
Department of Neurology, Royal Victoria Hospital, Grosvenor Road, Belfast BT12 6BA, UK; jim.morrow{at}royalhospitals.n-i.nhs.uk
Objective: To assess the relative risk of major congenital malformation (MCM) from in utero exposure to antiepileptic drug (AEDs).
Methods: Prospective data collected by the UK Epilepsy and Pregnancy Register were analysed. The presence of MCMs recorded within the first three months of life was the main outcome measure.
Results: Full outcome data were collected on 3607 cases. The overall MCM rate for all AED exposed cases was 4.2% (95% confidence interval (CI), 3.6% to 5.0%). The MCM rate was higher for polytherapy (6.0%) (n = 770) than for monotherapy (3.7%) (n = 2598) (crude odds ratio (OR) = 1.63 (p = 0.010), adjusted OR = 1.83 (p = 0.002)). The MCM rate for women with epilepsy who had not taken AEDs during pregnancy (n = 239) was 3.5% (1.8% to 6.8%). The MCM rate was greater for pregnancies exposed only to valproate (6.2% (95% CI, 4.6% to 8.2%) than only to carbamazepine (2.2% (1.4% to 3.4%) (OR = 2.78 (p<0.001); adjusted OR = 2.97 (p<0.001)). There were fewer MCMs for pregnancies exposed only to lamotrigine than only to valproate. A positive dose response for MCMs was found for lamotrigine (p = 0.006). Polytherapy combinations containing valproate carried a higher risk of MCM than combinations not containing valproate (OR = 2.49 (1.31 to 4.70)).
Conclusions: Only 4.2% of live births to women with epilepsy had an MCM. The MCM rate for polytherapy exposure was greater than for monotherapy exposure. Polytherapy regimens containing valproate had significantly more MCMs than those not containing valproate. For monotherapy exposures, carbamazepine was associated with the lowest risk of MCM.
Abbreviations: AED, antiepileptic drug; EUROCAT, European Surveillance of Congenital Anomalies; MCM, major congenital malformation
Keywords: epilepsy; pregnancy; teratogenicity; antiepileptic drugs
Relevant Article
J. Neurol. Neurosurg. Psychiatry 2006 77: 145.
This article has been cited by other articles:
|
|
 |
|
  K. J. Meador, P. B. Pennell, C. L. Harden, J. C. Gordon, T. Tomson, P. W. Kaplan, G. L. Holmes, J. A. French, W. A. Hauser, P. G. Wells, et al. Pregnancy registries in epilepsy: A consensus statement on health outcomes Neurology, September 30, 2008; 71(14): 1109 - 1117. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. J. Meador and P. Penovich What is the risk of orofacial clefts from lamotrigine exposure during pregnancy? Neurology, September 2, 2008; 71(10): 706 - 707. [Full Text] [PDF]
|
|
|
|
|
|
H. Dolk, J. Jentink, M. Loane, J. Morris, L.T.W. de Jong-van den Berg, and On behalf of The EUROCAT Antiepileptic Drug Workin Does lamotrigine use in pregnancy increase orofacial cleft risk relative to other malformations? Neurology, September 2, 2008; 71(10): 714 - 722. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P M Rothwell Prognostic models Practical Neurology, August 1, 2008; 8(4): 242 - 253. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Hunt, A. Russell, W. H. Smithson, L. Parsons, I. Robertson, R. Waddell, B. Irwin, P. J. Morrison, J. Morrow, and J. Craig Topiramate in pregnancy: Preliminary experience from the UK Epilepsy and Pregnancy Register Neurology, July 22, 2008; 71(4): 272 - 276. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Newport, P. B. Pennell, M. R. Calamaras, J. C. Ritchie, M. Newman, B. Knight, A. C. Viguera, J. Liporace, and Z. N. Stowe Lamotrigine in Breast Milk and Nursing Infants: Determination of Exposure Pediatrics, July 1, 2008; 122(1): e223 - e231. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. B. Pennell, L. Peng, D. J. Newport, J. C. Ritchie, A. Koganti, D. K. Holley, M. Newman, and Z. N. Stowe Lamotrigine in pregnancy: Clearance, therapeutic drug monitoring, and seizure frequency Neurology, May 27, 2008; 70(22_Part_2): 2130 - 2136. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. B. Holmes, E. J. Baldwin, C. R. Smith, E. Habecker, L. Glassman, S. L. Wong, and D. F. Wyszynski Increased frequency of isolated cleft palate in infants exposed to lamotrigine during pregnancy Neurology, May 27, 2008; 70(22_Part_2): 2152 - 2158. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Montouris Importance of monotherapy in women across the reproductive cycle Neurology, December 11, 2007; 69(24_suppl_3): S10 - S16. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S Macleod and R E Appleton The new antiepileptic drugs Arch. Dis. Child. Ed. Pract., December 1, 2007; 92(6): 182 - 188. [Full Text] [PDF]
|
|
|
|
 |
|
 L. James, T. R.E. Barnes, P. Lelliott, D. Taylor, and C. Paton Informing patients of the teratogenic potential of mood stabilizing drugs: a case note review of the practice of psychiatrists J Psychopharmacol, November 1, 2007; 21(8): 815 - 819. [Abstract] [PDF]
|
|
|
|
 |
|
 S. Shor, G. Koren, and I. Nulman Teratogenicity of lamotrigine Can Fam Physician, June 1, 2007; 53(6): 1007 - 1009. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Rennie and G. Boylan Treatment of neonatal seizures Arch. Dis. Child. Fetal Neonatal Ed., March 1, 2007; 92(2): F148 - F150. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Kalviainen and T. Tomson Optimizing treatment of epilepsy during pregnancy Neurology, December 26, 2006; 67(12_suppl_4): S59 - S63. [Abstract] [Full Text]
|
|
|
|
|
|
S. Hunt, J. Craig, A. Russell, E. Guthrie, L. Parsons, I. Robertson, R. Waddell, B. Irwin, P. J. Morrison, and J. Morrow Levetiracetam in pregnancy: Preliminary experience from the UK Epilepsy and Pregnancy Register Neurology, November 28, 2006; 67(10): 1876 - 1879. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Tomson, G. Luef, A. Sabers, S. Pittschieler, and I. Ohman Valproate effects on kinetics of lamotrigine in pregnancy and treatment with oral contraceptives. Neurology, October 10, 2006; 67(7): 1297 - 1299. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. P Breen and R. J Davenport Teratogenicity of antiepileptic drugs BMJ, September 23, 2006; 333(7569): 615 - 616. [Full Text] [PDF]
|
|
|
|
|
|
P. M Rothwell Medical academia is failing patients and clinicians. BMJ, April 15, 2006; 332(7546): 863 - 864. [Full Text] [PDF]
|
|
|
|
|
|
Teratogenicity of anti-epileptic drugs Arch. Dis. Child. Ed. Pract., April 1, 2006; 91(1): ep24 - ep24. [Full Text] [PDF]
|
|
|
|
|
|
E. Reynolds Treating refractory epilepsy in adults BMJ, March 11, 2006; 332(7541): 562 - 563. [Full Text] [PDF]
|
|
|
|
|
|
H. Marcovitch What's new this month in BMJ Journals. BMJ, February 25, 2006; 332(7539): 476 - 476. [Full Text] [PDF]
|
|
Read all eLetters
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
